Combination therapy for treatment of myeloproliferative neoplasms
UA131207C2Undetermined Publication Date: 2026-09-16INCYTE CORP
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- UA · UA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-14
- Filing Date
- 2020-09-14
- Publication Date
- 2026-09-16
Abstract
The present application relates to treatment of myeloproliferative neoplasms using the JAK1 / JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
Need to check novelty before this filing date? Find Prior Art